Connect Sign In
Adalimumab and Antibodies to Adalimumab Quantitation
Ordering Recommendation
Use to monitor adalimumab or adalimumab biosimilar therapy.
New York DOH Approval Status
Specimen Required
Collect specimens before next scheduled dose of adalimumab or adalimumab biosimilar (trough specimen). Avoid exposure to biotin (vitamin B7) for 12 hours prior to specimen collection.
Serum separator tube.
Separate serum from cells ASAP. Transfer 1 mL serum to an ARUP standard transport tube. (Min 0.1 mL)
New York State Clients: 2 mL (Min: 1 mL)
Refrigerated.
Grossly hemolyzed, icteric, or lipemic specimens.
After separation from cells: Ambient: 2 days; Refrigerated: 2 weeks; Frozen: 1 month (avoid repeated freeze/thaw cycles).
New York State Clients: Ambient: 1 week; Refrigerated: 1 week; Frozen: 308 days
Methodology
Quantitative Electrochemiluminescent Immunoassay (ECLIA) with Acid Dissociation
Performed
Sun-Sat
Reported
3-7 days
Reference Interval
Interpretive Data
Adalimumab Quantitation:
Limit of Quantitation = 0.4 ug/mL.
Results of 0.4 ug/mL or higher indicate the detection of adalimumab or an adalimumab biosimilar. Therapeutic level may vary depending on the disease being treated.
Antibodies to Adalimumab Quantitation:
Limit of Quantitation = 20 ng/mL
Results of 20 ng/mL or higher indicate the detection of antibodies against adalimumab or an adalimumab biosimilar. Interpret in the context of adalimumab or adalimumab biosimilar trough concentration to determine clinical significance and impact on treatment efficacy.
Laboratory Developed Test (LDT)
Note
Hotline History
Hotline History
CPT Codes
80145; 82397
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 3017044 | Adalimumab Quantitation | 86894-3 |
| 3017045 | Antibodies to Adalimumab Quantitation | 86895-0 |
Aliases
- Abrilada
- Amjevita
- Cyltezo
- Hadlima
- Hulio
- Humira
- Hymiroz
- Idacio
- Yusimry
